×
ADVERTISEMENT

JULY 19, 2021

FAQ: Is There a Role for IG in the Treating MIS-C?

Jerry Siegel, PharmD, FASHP
Clinical Associate Professor
The Ohio State University College of Pharmacy
Columbus, Ohio 
VP Business Development
Managing Partner, Safe Medication Management
East Greenwich, Rhode Island

MIS-C is a multisystem inflammatory syndrome in children. It was first reported in April 2020, in England, in a cluster of children with hyperinflammatory shock with features similar to Kawasaki disease and toxic shock syndrome.1 The clinical signs and symptoms present in this first